Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: We aimed to develop a standardized method to calculate daily dose (i.e., the amount of drug a patient was exposed to per day) of any drug on a global scale using only drug information of typical observational data in the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) and a single reference table from Observational Health Data Sciences And Informatics (OHDSI).
Materials And Methods: The OMOP DRUG_STRENGTH reference table contains information on the strength or concentration of drugs, whereas the OMOP DRUG_EXPOSURE table contains information on patients' drug prescriptions or dispensations/claims. Based on DRUG_EXPOSURE data from the primary care databases Clinical Practice Research Datalink GOLD (United Kingdom) and Integrated Primary Care Information (IPCI, The Netherlands) and healthcare claims from PharMetrics® Plus for Academics (USA), we developed four formulas to calculate daily dose given different DRUG_STRENGTH reference table information. We tested the dose formulas by comparing the calculated median daily dose to the World Health Organization (WHO) Defined Daily Dose (DDD) for six different ingredients in those three databases and additional four international databases representing a variety of healthcare settings: MAITT (Estonia, healthcare claims and discharge summaries), IQVIA Disease Analyzer Germany (outpatient data), IQVIA Longitudinal Patient Database Belgium (outpatient data), and IMASIS Parc Salut (Spain, hospital data). Finally, in each database, we assessed the proportion of drug records for which daily dose calculations were possible using the suggested formulas.
Results: Applying the dose formulas, we obtained median daily doses that generally matched the WHO DDD definitions. Our dose formulas were applicable to >85% of drug records in all but one of the assessed databases.
Conclusion: We have established and implemented a standardized daily dose calculation in OMOP CDM providing reliable and reproducible results.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pds.5809 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topical Glucocorticoid-Induced Cushing's Syndrome in a Patient with Erythrodermic Psoriasis: A Case Report.
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology, Wuhan Asia General Hospital, Wuhan Asia General Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, 430000, People's Republic of China.
Background: Topical glucocorticoids are widely used in psoriasis treatment but may lead to systemic adverse effects, particularly with prolonged use. While pediatric cases are well-documented, adult-onset iatrogenic Cushing's syndrome from topical corticosteroids remains under-recognized.
Case Presentation: A 31-year-old woman with a 10-year history of psoriasis vulgaris self-administered high-potency clobetasol propionate ointment (monthly cumulative dose escalated from 30 g to 100 g over 22 months) under no physician supervision.
Mitigation of mycotoxin residues and activation of endogenous stem cells in broiler chickens using a toxin binder: Implications for meat safety and performance enhancement.
Vet World
July 2025
Laboratory of Theriogenology Joint Faculty of Veterinary Medicine, Yamaguchi University, Yamaguchi, Japan.
Background And Aim: Mycotoxin contamination in poultry feed, particularly with aflatoxin B1 (AFB1) and ochratoxin A (OTA), poses significant threats to broiler health, meat quality, and consumer safety. Toxin binders are commonly used to mitigate these effects; however, their impact on endogenous stem cell activity and overall broiler performance remains underexplored. This study aimed to evaluate the efficacy of a commercial toxin binder in reducing AFB1 and OTA residues in broiler meat, inducing endogenous stem cell production, and improving growth and feed performance indices.
View Article and Find Full Text PDFAssociation between changes in secondhand smoke exposure and incident metabolic syndrome among Korean former smokers.
Nutr Metab Cardiovasc Dis
August 2025
Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Background And Aims: Although secondhand smoke (SHS) exposure has been linked with metabolic syndrome (MetS) in never-smokers, its effects among individuals who have quit smoking remain unclear. This study investigated the relationship between changes in SHS exposure and incident MetS in a large cohort of Korean former smokers.
Methods And Results: We analyzed 17,269 Korean former smokers without MetS at baseline from a longitudinal cohort, with a median follow-up of three years.
A qualitative study to explore experiences and views of patients and their family members managing steroid-induced hyperglycaemia (SIH) out of hospital.
Diabet Med
September 2025
Endocrinology Department, East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust, Redhill, UK.
Aim: To explore the experiences of patients, families and clinicians managing steroid-induced hyperglycaemia (SIH) out of the hospital and identify areas for improved care.
Methods: We searched hospital records to identify patients requiring input from the diabetes inpatient team between February 2022 and March 2023 due to steroid usage. Clinicians, patients and their family members were interviewed remotely about their experiences of care and views on how to improve it.
[Advanced Hybrid Closed Loop (AHCL) System for Glucose Monitoring and Automatic Insulin Microinfusion in Dialysis].
G Ital Nefrol
August 2025
Infermiere Professionale SSD Nefrologia e Dialisi P.O. Soverato, ASP CZ.
Management of diabetes mellitus in hemodialysis is highly complex due to increased glycemic variability and hypoglycemic risk. The use of technologies applied to diabetes has been shown to improve glycemic control, however data in dialysis patients are limited. To describe the efficacy and safety of the minimed 780G AHCL system in a stable hemodialysis patient and during hospitalization in the Intensive Care Unit (ICU).
View Article and Find Full Text PDF